ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO1033

Incidence of Biopsy-Proven Kidney Disease Among Kaiser Permanente Northern California Patients in 2018

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Charu, Vivek, Stanford University School of Medicine, Palo Alto, California, United States
  • Aghighi, Maryam, Stanford University School of Medicine, Palo Alto, California, United States
  • Lapasia, Jessica B., The Permanente Medical Group, Northern California, California, United States
  • Lai, George, The Permanente Medical Group, Northern California, California, United States
  • Lin, Jennifer W., The Permanente Medical Group, Northern California, California, United States
  • Jonelis, Tracy Y., The Permanente Medical Group, Northern California, California, United States
  • Troxell, Megan L., Stanford University School of Medicine, Palo Alto, California, United States
  • Kambham, Neeraja, Stanford University School of Medicine, Palo Alto, California, United States
  • Zheng, Sijie, The Permanente Medical Group, Northern California, California, United States
Background

Accurate population-level estimates of the incidence of glomerular (G) and primary tubulointerstitial diseases (TI) are lacking. Obtaining such estimates is challenging as accurate diagnosis typically requires a kidney biopsy and lack relevant population-level denominators. Here we provide population-level estimates of biopsy-proven G & TI diseases in a cohort of ~4.3 million at Kaiser Permanente Northern California (KPNC) in 2018.

Methods

We reviewed all KPNC 2018 renal biopsy reports, and categorized patients into known G & TI disease groups. Incidence rates and associated standard deviations were calculated per 100,000 persons, stratified by age and sex.

Results

673 native kidney biopsies were performed in 2018, corresponding to 15.8 biopsies/100,000 persons. The incidence of common biopsy-confirmed G & TI diseases are provided in the Table. IgA nephropathy is the most common diagnosis (incidence 2.3/100,000 persons), followed by focal and segmental glomerulosclerosis (1.6/100,000), lupus nephritis (1.4/100,000), pauci-immune GN (1.3/100,000), and membranous nephropathy (1.3/100,000). 19.5% patients undergoing kidney biopsy in this cohort had evidence of diabetic nephropathy (n=131), 21.4% of whom had an additional G or TI diagnosis (n=28).

Conclusion

Here we provide incidence estimates of biopsy-confirmed G & TI diseases in a large, racially and ethnically diverse population. Comparison with population-level estimates in other cohorts will help determine the true incidence of these diseases.

Biopsy-proven kidney disease, KPNC, 2018. *Incidence rates/100,000 persons
 Total
(rate*; SE)
Males
(rate*; SE)
Females
(rate*; SE)
All biopsies673 (15.8; 0.6)339 (15.4; 0.8)334 (16.3; 0.9)
IgA nephropathy96 (2.3; 0.2)50 (2.3; 0.3)46 (2.2; 0.3)
Focal and segmental
glomerulosclerosis
70 (1.6; 0.2)45 (2.0; 0.3)25 (1.2; 0.2)
Lupus nephritis58 (1.4; 0.2)7 (0.3; 0.1)51 (2.5; 0.3)
Pauci-immune glomerulonephritis55 (1.3; 0.2)20 (0.9; 0.2)35 (1.7; 0.3)
Membranous nephropathy55 (1.3; 0.2)33 (1.5; 0.3)22 (1.1; 0.2)
Light chain cast nephropathy and monoclonal gammopathies of renal significance22 (0.5; 0.1)11 (0.5; 0.2)11 (0.5; 0.2)
Acute tubular injury21 (0.5; 0.1)11 (0.5; 0.2)10 (0.5; 0.2)
Minimal change disease19 (0.5; 0.1)10 (0.5; 0.1)9 (0.4; 0.2)
Thrombotic microangiopathy19 (0.5; 0.1)9 (0.4; 0.1)10 (0.5; 0.2)
Acute interstitial nephritis17 (0.4; 0.1)7 (0.3; 0.1)10 (0.5; 0.2)
Infection-associated glomerulonephritis15 (0.2; 0.1)12 (0.5; 0.2)3 (0.2; 0.1)
Amyloidosis14 (0.3; 0.1)5 (0.2; 0.1)9 (0.4; 0.2)